357 related articles for article (PubMed ID: 33957435)
1. Characteristics and evaluation of acute exacerbations in chronic interstitial lung diseases.
Kershaw CD; Batra K; Torrealba JR; Terada LS
Respir Med; 2021 Jul; 183():106400. PubMed ID: 33957435
[TBL] [Abstract][Full Text] [Related]
2. Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?
de Lauretis A; Veeraraghavan S; Renzoni E
Chron Respir Dis; 2011; 8(1):53-82. PubMed ID: 21339375
[TBL] [Abstract][Full Text] [Related]
3. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
[TBL] [Abstract][Full Text] [Related]
4. Acute exacerbations of fibrosing interstitial lung disease associated with connective tissue diseases: a population-based study.
Cao M; Sheng J; Qiu X; Wang D; Wang D; Wang Y; Xiao Y; Cai H
BMC Pulm Med; 2019 Nov; 19(1):215. PubMed ID: 31727051
[TBL] [Abstract][Full Text] [Related]
5. Causes of acute respiratory hospitalizations predict survival in fibrosing interstitial lung diseases.
Salonen J; Vähänikkilä H; Purokivi M; Kaarteenaho R
PLoS One; 2020; 15(11):e0242860. PubMed ID: 33253258
[TBL] [Abstract][Full Text] [Related]
6. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
7. Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.
Singer D; Bengtson LGS; Conoscenti CS; Laouri M; Shetty SS; Anderson AJ; Brown KK
Ann Am Thorac Soc; 2022 Jul; 19(7):1112-1121. PubMed ID: 35015982
[No Abstract] [Full Text] [Related]
8. Patterns and Economic Burden of Hospitalizations and Exacerbations Among Patients Diagnosed with Idiopathic Pulmonary Fibrosis.
Yu YF; Wu N; Chuang CC; Wang R; Pan X; Benjamin NN; Devercelli G; Coultas DB
J Manag Care Spec Pharm; 2016 Apr; 22(4):414-23. PubMed ID: 27023695
[TBL] [Abstract][Full Text] [Related]
9. Association of the RAGE/RAGE-ligand axis with interstitial lung disease and its acute exacerbation.
Yamaguchi K; Iwamoto H; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Fujitaka K; Hamada H; Hattori N
Respir Investig; 2022 Jul; 60(4):531-542. PubMed ID: 35504814
[TBL] [Abstract][Full Text] [Related]
10. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
Gibson CD; Kugler MC; Deshwal H; Munger JS; Condos R
Lung; 2020 Aug; 198(4):597-608. PubMed ID: 32591895
[TBL] [Abstract][Full Text] [Related]
11. Association between Pepsin in Bronchoalveolar Lavage Fluid and Prognosis of Chronic Fibrosing Interstitial Lung Disease.
Kim Y; Lee YJ; Cho YJ; Yoon HI; Lee JH; Lee CT; Park JS
Tohoku J Exp Med; 2018 Nov; 246(3):147-153. PubMed ID: 30405002
[TBL] [Abstract][Full Text] [Related]
12. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
Olson AL; Maher TM; Acciai V; Mounir B; Quaresma M; Zouad-Lejour L; Wells CD; De Loureiro L
Adv Ther; 2020 Jul; 37(7):3292-3298. PubMed ID: 32451950
[TBL] [Abstract][Full Text] [Related]
13. Prognosis after acute exacerbation in patients with interstitial lung disease other than idiopathic pulmonary fibrosis.
Miyashita K; Kono M; Saito G; Koyanagi Y; Tsutsumi A; Kobayashi T; Miki Y; Hashimoto D; Nakamura Y; Suda T; Nakamura H
Clin Respir J; 2021 Mar; 15(3):336-344. PubMed ID: 33197284
[TBL] [Abstract][Full Text] [Related]
14. Acute exacerbations of interstitial lung disease: lessons from idiopathic pulmonary fibrosis.
Spagnolo P; Wuyts W
Curr Opin Pulm Med; 2017 Sep; 23(5):411-417. PubMed ID: 28582317
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory treatment of interstitial lung disease.
van den Bosch L; Luppi F; Ferrara G; Mura M
Ther Adv Respir Dis; 2022; 16():17534666221117002. PubMed ID: 35938712
[TBL] [Abstract][Full Text] [Related]
16. Distinctive characteristics and prognostic significance of interstitial pneumonia with autoimmune features in patients with chronic fibrosing interstitial pneumonia.
Yoshimura K; Kono M; Enomoto Y; Nishimoto K; Oyama Y; Yasui H; Hozumi H; Karayama M; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Inui N; Sumikawa H; Johkoh T; Colby TV; Sugimura H; Suda T
Respir Med; 2018 Apr; 137():167-175. PubMed ID: 29605201
[TBL] [Abstract][Full Text] [Related]
17. Corticosteroid responsiveness in patients with acute exacerbation of interstitial lung disease admitted to the emergency department.
Jang HJ; Yong SH; Leem AY; Lee SH; Kim SY; Lee SH; Kim EY; Chung KS; Jung JY; Kang YA; Kim YS; Chang J; Park MS
Sci Rep; 2021 Mar; 11(1):5762. PubMed ID: 33707643
[TBL] [Abstract][Full Text] [Related]
18. Impact of antifibrotic therapy on disease progression, all-cause mortality, and risk of acute exacerbation in non-IPF fibrosing interstitial lung diseases: evidence from a meta-analysis of randomized controlled trials and prospective controlled studies.
Li DY; Liu X; Huang JY; Hang WL; Yu GR; Xu Y
Ther Adv Respir Dis; 2024; 18():17534666241232561. PubMed ID: 38414439
[TBL] [Abstract][Full Text] [Related]
19. Rapidly non-ipf progressive fibrosing interstitial lung disease: a phenotype with an ipf-like behavior.
Khine N; Mudawi D; Rivera-Ortega P; Leonard C; Chaudhuri N; Margaritopoulos GA
Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):231-233. PubMed ID: 33093788
[TBL] [Abstract][Full Text] [Related]
20. Acute exacerbation of interstitial lung disease after procedures.
Amundson WH; Racila E; Allen T; Dincer HE; Tomic R; Bhargava M; Perlman DM; Kim HJ
Respir Med; 2019 Apr; 150():30-37. PubMed ID: 30961948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
